breast cancer

Immutep Limited (NASDAQ: IMMP) has announced final overall survival data (OS) from its Phase 2b AIPAC trial. 227 patients with HER2-negative/HR-positive metastatic breast cancer (HR+ MBC) were 1:1 randomized in the AIPAC study.  The trial evaluated Immutep's eftilagimod...

The Menarini Group and Radius Health Inc (NASDAQ: RDUS) have announced topline results from the EMERALD Phase 3 study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer patients. There were two primary endpoints...

eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zotatifin in animal models of triple-negative breast cancer (TNBC). The data were at the 2021 AACR-NCI-EORTC International Conference...

Health Canada has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for previously treated breast cancer patients. The approval comes for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have...

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor tests.  What Happened: The Phase 3 DESTINY-Breast03 head-to-head study included second-line unresectable or...

Novartis AG (NYSE: NVS) announced results of the final overall survival (OS) analysis of Phase 3 MONALEESA-2 study, which evaluated Kisqali (ribociclib) in combination with letrozole in breast cancer patients. The trial compared the combination therapy to placebo plus letrozole in...

Merck & Co Inc (NYSE: MRK) announced the final overall survival (OS) results from the Phase 3 KEYNOTE-355 trial of Keytruda in combination with chemotherapy for the first-line metastatic triple-negative breast cancer (mTNBC).  Keytruda combined with chemotherapy (paclitaxel...

Gilead Sciences Inc (NASDAQ: GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies. The results were presented at the...

MacroGenics Inc (NASDAQ: MGNX) scored a big win with its full approval for anti-HER2 drug Margenza in December 2020 based on a head-to-head matchup with breast cancer med Herceptin.  But Margenza's overall survival (OS) data could spell a rough road ahead for the drug....

Following a consultation from the FDA, Roche Holdings AG (OTC: RHHBY) has decided to withdraw its immunotherapy, Tecentriq (atezolizumab), to treat a type of breast cancer in the U.S. Earlier this year, Roche withdrew the drug from the U.S. to treat bladder cancer after follow-...

BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation immuno-oncology imaging agents and radiopharmaceutical therapies. Under the agreement terms, ImaginAb will supply clinical...

Plus Therapeutics Inc (NASDAQ: PSTV) has presented preclinical data of its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), for leptomeningeal metastases (LM). The data were presented at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-...

AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3 trial of Enhertu. The trial reached its primary endpoint in a study including HER2-positive metastatic breast cancer...

Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49 patients were enrolled in the MARIO-275 study designed to evaluate it as a combination therapy with Bristol-Myers...

Merck & Co Inc (NYSE: MRK) has announced overall survival (OS) results from Phase 3 KEYNOTE-355 trial evaluating Keytruda (pembrolizumab) in combination with chemotherapy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). Final analysis show...